Digital pathology company Paige has secured FDA Breakthrough Device Designation for Paige PanCancer Detect, an artificial intelligence system designed to flag suspicious tissue across dozens of organs and tissue types on a single digitized slide. The designation, announced in the spring, marks the first time the FDA has granted breakthrough status to an AI tool built to catch both common cancers and rare variants across a wide range of anatomic sites, rather than a single cancer type.
From 17 Tissue Types to 40
Paige PanCancer Detect launched in early 2024 with the ability to analyze 17 tissue types. Since then, the company has expanded the model’s coverage to 40 tissue and organ types, including gastrointestinal, genito-urinary, breast, skin, and brain tissue, according to Paige. The tool is intended to sit alongside a pathologist’s workflow, scanning whole-slide images and highlighting regions that warrant a closer look, in effect acting as a second set of eyes trained on an enormous archive of prior cases.
Why Pathologists Need the Help
The case for a pan-cancer AI screen rests on a structural problem in pathology: the number of practicing pathologists in the United States has been shrinking even as biopsy volume climbs with an aging population and more aggressive cancer screening guidelines. Paige has argued publicly that ‘AI-powered tools like Paige PanCancer Detect are becoming essential in closing’ the widening gap between the demand for pathology services and the pathologists available to read them. Dr. David Klimstra, Paige’s co-founder and former chief medical officer, said the breakthrough designation ‘demonstrates the significance of AI in transforming cancer diagnostics,’ and argued it can help pathologists concentrate their limited time on the most consequential cases rather than spreading attention evenly across a stack of slides.
A Track Record in a Single Cancer Type First
Paige is not new to FDA interactions. The company previously won clearance for Paige ProstateDetect, a narrower tool focused specifically on identifying prostate cancer in biopsy tissue, which gave the company a template for how the agency evaluates pathology AI and a base of real-world deployment data to point to when making the case for a far broader, pan-cancer successor.
Still Early, Still Research-Only
Despite the attention the breakthrough designation has generated, PanCancer Detect remains, by the company’s own description, in an experimental stage limited to research use; it does not yet have FDA clearance to be used for primary diagnosis in a clinical setting. Breakthrough Device Designation itself is not a marketing authorization. It is a fast-track status meant to speed up the FDA’s review process, offering more frequent interaction with agency reviewers, but the company still needs to complete clinical validation and submit for actual clearance or approval before hospitals can use the tool to make diagnostic calls that affect patient care.
Reasons for Caution
Broad, multi-organ AI screening tools raise a distinct set of validation challenges compared to single-cancer algorithms. A model trained to recognize dozens of tissue types must be tested separately against the particular staining patterns, tissue architecture, and disease prevalence of each organ system, and a tool that performs well on common cancers can still underperform on rarer subtypes that appear too infrequently in training data to be learned reliably. Independent researchers who study the broader landscape of FDA-cleared AI have repeatedly pointed out that only a small fraction of cleared algorithms have published outcomes data showing they change what happens to patients, as opposed to simply matching the accuracy of a predicate reader. A pan-cancer tool covering 40 tissue types will face pressure to show organ-by-organ performance data before regulators and hospital labs treat its findings as reliable across the board.
What’s Next
Paige is expected to use the breakthrough designation to accelerate discussions with the FDA toward a formal clearance submission, likely phased by tissue type or clinical use case rather than as a single blanket approval. If the company can show consistent performance across its expanded organ list, PanCancer Detect could become one of the most consequential pathology AI products yet cleared, given how directly it targets the pathologist shortage that hospital labs across the country are already grappling with.
